Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: High immunogenicity of HLA class II graft molecules

Transplant International

Volumn 24, Issue 11, 2011, Pages 1084-1093

  Ntokou, Irma Sofia A ^a   Iniotaki, Aliki G ^a   Kontou, Elissavet N ^a   Darema, Maria N ^b   Apostolaki, Maria D ^a   Kostakis, Alkibiadis G ^b   Boletis, John N ^b  

^a IASO GENERAL HOSPITAL   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

de novo donor specific antibodies; graft failure; human leukocyte antigens class II antibodies; renal transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; HLA ANTIBODY; HLA ANTIGEN CLASS 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; BLOOD SAMPLING; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOGENICITY; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOLECULE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK;

ADULT; ANTIBODIES; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY ANTIGENS CLASS II; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HLA-DQ ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TISSUE DONORS; TREATMENT OUTCOME;

EID: 80053989810     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01312.x     Document Type: Article

References (37)

1. Cecka JM, Terasaki PI,. The UNOS scientific renal transplant registry. In:, Terasaki PI, ed. Clinical Transplants. Los Angeles, CA: UCLA Tissue Typing Laboratory, 1995: pp. 10-18.
2. Kaneku HK, Terasaki PI,. Thirty year trend in kidney transplants: UCLA and UNOS renal transplant registry. In:, Terasaki PI, ed. Clinical Transplants. Los Angeles, CA: Terasaki Foundation Laboratory, 2006: pp. 1-27.
3. Scornick JC, Salomon DR, Lim PB, Howard RJ, Pfaff WW,. Posttransplant antibodies and graft rejection: evaluation by two-color flow cytometry. Transplantation 1989; 47: 287.
4. Piazza A, Poggi E, Borrelli L, et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: posttransplant analysis using flow cytometry techniques. Transplantation 2001; 71: 1106.
5. Terasaki PI, Ozawa M,. Predicting kidney graft failure by HLA antibodies: α prospective trial. Am J Transplant 2004; 4: 438.
6. Arnold ML, Pei R, Spriewald B, Wassmuth R,. Anti-HLA class II antibodies in kidney retransplant patients. Tissue Antigens 2005; 65: 370.
7. Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 1192.
8. Worthington JE, Martin S, Al-Husseini DM, Dyer PA, Johnson RW,. Post-transplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034.
9. El-Awar N, Lee J, Terasaki PI,. HLA antibody identification with single antigen beads compared to conventional methods. Hum Immunol 2005; 66: 989.
10. Couzi L, Araujo C, Guidicelli G, et al. Interpretation of positive flow cytometric crossmatch in the era of the single antigen bead assay. Transplantation 2011; 91: 527.
11. Rentenaar RJ, Van Diepen FNJ, Meijer RT, et al. Immune responsiveness in renal transplant recipients: Mycophenolic acid severelly depresses humoral immunity in vivo. Kidney Int 2002; 62: 319.
12. McKena RM, Takemoto SK, Terasaki Pl,. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000; 69: 319.
13. Terasaki PI, Ozawa M,. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2- year prospective trial. Transplantation 2005; 80: 1194.
14. Pelletier RP, Hennessy PK, Adams PW, VanBurkirk AM, Ferguson RM, Orosz CG,. Cinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation. Am J Transplant 2002; 2: 134.
15. Campos F, Tedesco-Silva H, Machado PG, Franco M, Medina-Pestana JO, Gerbase-DeLima M,. Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006; 6: 2316.
16. Terasaki PI, Mickey MR, Kreisler M,. Presensitization and kidney transplant failure. Postgrad Med J 1971; 47: 89.
17. Opelz G,. Kidney transplantation in sensitized patients. Transplant Proc 1987; 19: 3737.
18. Susal C, Dohler B, Opelz G,. Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: A Collaborative Transplant Sudy report. Hum Immunol 2009; 70: 569.
19. Feucht HE, Opelz G,. The humoral immune response towards HLA class II determinants in renal transplantation. Kidney Int 1996; 50: 1464.
20. Schonemann C, Groth J, Leverenz S, May G,. HLA class I and class II antibodies. Transplantation 1998; 65: 1519.
21. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532.
22. Haririan A, Kiangkitiwan B, Kukuruga D, et al. The impact of C4d pattern and donor-specific antibody on graft survival in recipients requiring indication renal allograft biopsy. Am J Transplant 2009; 9: 2758.
23. Doxiadis II, De Fijter JW, Mallat MJ, et al. Simpler and equitable allocation of kidneys from postmortem donors primarily based on full HLA-DR compatibility. Transplantation 2007; 83: 1207.
24. Hourmant M, Cesbron-Gautier A, Terasaki P, et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16: 2804.
25. Suciu-Foca N, Î - arris PE, Cortesini R,. Intramolecular and intermolecular spreading during the course of organ allograft rejection. Immunol Rev 1998; 164: 241.
26. Iniotaki-Theodoraki AG, Boletis JN, Trigas GC, Kalogeropoulou HG, Kostakis AG, Stavropoulos-Giokas CG,. Humoral immune reactivity against human leukocyte antigen (HLA)-DQ graft molecules in the early posttransplant period. Transplantation 2003; 75: 1601.
27. Varnabidou-Nicolaidou A, Iniotaki-Theodoraki AG, Doxiadis IIN, et al. Expansion of humoral donor-specific alloreactivity after renal transplantation correlates with impaired graft outcome. Hum Immunol 2005; 66: 985.
28. Deng CT, El-Awar N, Ozawa M, Cai J, Lachmann N, Terasaki PI,. Human leukocyte antigen class II DQ alpha and beta epitopes identified from sera of kidney allograft recipients. Transplantation 2008; 86: 452.
29. Iniotaki-Theodoraki A, Douramani P, Boletis J, et al. Immune reactivity towards HLA class II determinants in renal transplantation. Transplant Proc 2001; 33: 461.
30. Lee PC, Zhu L, Terasaki PI, Everly MJ,. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88: 568.
31. Cai J, Terasaki PI,. Humoral theory of transplantation: mechanisms, prevention and treatment. Hum Immunol 2005; 66: 334.
32. Tincman KJ, Chandraker A,. Mechanisms and role of HLA and non-HLA alloantibodies. Clin J Am Soc Nephrol 2006; 1: 404.
33. Colvin RB,. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046.
34. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505.
35. Zhang Q, Liang LW, Gjertson DW, et al. Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation 2005; 79: 591.
36. Zhang Q, Reed EF,. Non-MHC antigenic targets of the humoral immune response in transplantation. Cur Opin Immunol 2010; 22: 682.
37. Cai J, Terasaki PI, Mao Q, et al. Development of non-donor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens. Am J Transplant 2006; 6: 2947.